TrialFrontiers in immunology2026

Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial.

Zhenyu Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.